24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Ronny Gal
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
20:51
Deel CEO Alex Bouaziz surfaces in Dubai as Rippling struggles to serve lawsuit
19:45
Full list of Israeli startup M&As in 2025
19:43
CloudShare acquired by Bow River Capital in estimated $60–80 million deal
18:07
Safe Superintelligence is valued at $32B and doesn’t want you to know it exists
More stories
Buzz
Most popular
Daily
Weekly
1
Intel’s breakup begins with sale of $8.75B-valued Altera to private equity giant Silver Lake
2
Fintech Tapcheck raises $225M—$25M Series A extension and $200M facility—to expand real-time pay
3
Armis president sets bold goal: $1B in sales in three years, IPO in two
4
Deel CEO Alex Bouaziz surfaces in Dubai as Rippling struggles to serve lawsuit
5
Ilya Sutskever’s Safe Superintelligence raises $2B at $32B valuation—with no product yet
More news
Ronny Gal
1 stories about Ronny Gal
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18
|
Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
